In this study, we aimed to evaluate the megakaryocyte morphology, morphometry, and expression of markers representing BMMs such as CD44, CD48, CD150, vascular endothelial growth factor (VEGF), FOXP3, N-cadherin, osteopontin, PDL-1, and IL-7 and their association between disease progression and therapy resistance in CML. The gene discussed is CD44; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.